This old version of Proteopedia is provided for student assignments while the new version is undergoing repairs. Content and edits done in this old version of Proteopedia after March 1, 2026 will eventually be lost when it is retired in about June of 2026.


Apply for new accounts at the new Proteopedia. Your logins will work in both the old and new versions.


Sandbox Reserved 1369

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (21:56, 7 March 2018) (edit) (undo)
 
(4 intermediate revisions not shown.)
Line 9: Line 9:
The Mig-6/EGFR protein complex has great importance to the prevention and suppression of epithelial tumors. Since EGFR promotes epithelial growth, and therefore the growth of epithelial cancers when they occur, the Mig-6/EGFR complex is essentially a tumor suppressing complex, because Mig-6 inhibits the function of EGFR
The Mig-6/EGFR protein complex has great importance to the prevention and suppression of epithelial tumors. Since EGFR promotes epithelial growth, and therefore the growth of epithelial cancers when they occur, the Mig-6/EGFR complex is essentially a tumor suppressing complex, because Mig-6 inhibits the function of EGFR
== Relevance ==
== Relevance ==
-
Mig-6 is a feedback inhibitor that binds, inhibits, and drives internalization of ErbB-family receptors. Mig-6 inactivates the EGFR and thus is critical in better understanding human cancers2. EGFR phosphorylates Mig6 on Y394 and that this phosphorylation is primed by prior phosphorylation of an adjacent residue, Y395, by Src.
+
Mig-6 is a feedback inhibitor that binds, inhibits, and drives internalization of ErbB-family receptors. Mig-6 inactivates the EGFR and thus is critical in better understanding human cancers. EGFR phosphorylates Mig6 on Y394 and that this phosphorylation is primed by prior phosphorylation of an adjacent residue, Y395, by Src.
Somatic mutations in the EGFR kinase domain have been shown to drive lung adenocarcinoma, a specific type of lung cancer. Mig-6 is a target for phosphorylation by mutant EGFR’s and is a promising tumor suppressor for mutant-driven lung adenocarcinoma. During a research study, lung tumor formation progressed faster in mice lacking Mig-62. Interaction between Mig-6 and EGFR, stabilizes EGFR, inhibiting mutant EGFR, and preventing or delaying further growth of mutant EGFR-driven tumors.
Somatic mutations in the EGFR kinase domain have been shown to drive lung adenocarcinoma, a specific type of lung cancer. Mig-6 is a target for phosphorylation by mutant EGFR’s and is a promising tumor suppressor for mutant-driven lung adenocarcinoma. During a research study, lung tumor formation progressed faster in mice lacking Mig-62. Interaction between Mig-6 and EGFR, stabilizes EGFR, inhibiting mutant EGFR, and preventing or delaying further growth of mutant EGFR-driven tumors.
Line 24: Line 24:
There were13 important binding residues from MIG-6_s1 and 9 residues from EGFR kinase with binding free energies less than-1 kcal/mol. The 13 residues of MIG-6_s1 comprise Ser337, Leu338, and Ser361 whereas the 9 residues of EGFR kinase were Thr885, Glu904, and Ile929. Some of these residues, such as Pro910, had the values of the binding free energies less than or equal to -4 kcal/mol. Five residues of MIG-6_s1, namely Leu342, <scene name='77/777689/Ser337/1'>Ser337</scene>, and seven residues of EGFR kinase, namely Glu907, had their binding free energies approximately -1.0 kcal/mol.
There were13 important binding residues from MIG-6_s1 and 9 residues from EGFR kinase with binding free energies less than-1 kcal/mol. The 13 residues of MIG-6_s1 comprise Ser337, Leu338, and Ser361 whereas the 9 residues of EGFR kinase were Thr885, Glu904, and Ile929. Some of these residues, such as Pro910, had the values of the binding free energies less than or equal to -4 kcal/mol. Five residues of MIG-6_s1, namely Leu342, <scene name='77/777689/Ser337/1'>Ser337</scene>, and seven residues of EGFR kinase, namely Glu907, had their binding free energies approximately -1.0 kcal/mol.
-
These are the hydrogen bonds formed between residues <scene name='77/777689/Ser337/1’>SER337</scene>, and the residues Glu904, Gly906, Arg908, Gln911 and Ile929 of EGFR kinase. Strong, medium and weak hydrogen-bond interactions were defined as having simulated hydrogen bond occupancy of > 75%, 50–75%, and < 50%, respectively.
+
These are the hydrogen bonds formed between residues <scene name='77/777689/Asn343/1'>Asn343</scene> and the residues Glu904, Gly906, Arg908, Gln911 and Ile929 of EGFR kinase. Strong, medium and weak hydrogen-bond interactions were defined as having simulated hydrogen bond occupancy of > 75%, 50–75%, and < 50%, respectively.
-
We showed that there were six “hot spot” residues on EGFR kinase, namely Glu904, Glu907, Arg908, Gln911, Met928 and Ile929; and eight “hot spot” residues on MIG-6_s1, namely <scene name='77/777689/Leu338/1’>LEU338</scene>,.
+
We showed that there were six “hot spot” residues on EGFR kinase, namely Glu904, Glu907, Arg908, Gln911, Met928 and Ile929; and eight “hot spot” residues on MIG-6_s1, namely <scene name='77/777689/Leu338/3'>LEU338</scene>.
</StructureSection>
</StructureSection>

Current revision

This Sandbox is Reserved from January through July 31, 2018 for use in the course HLSC322: Principles of Genetics and Genomics taught by Genevieve Houston-Ludlam at the University of Maryland, College Park, USA. This reservation includes Sandbox Reserved 1311 through Sandbox Reserved 1430.
To get started:
  • Click the edit this page tab at the top. Save the page after each step, then edit it again.
  • Click the 3D button (when editing, above the wikitext box) to insert Jmol.
  • show the Scene authoring tools, create a molecular scene, and save it. Copy the green link into the page.
  • Add a description of your scene. Use the buttons above the wikitext box for bold, italics, links, headlines, etc.

More help: Help:Editing

EGFR kinase domain in complex with Mitogen-inducible gene 6 protein

Caption for this structure

Drag the structure with the mouse to rotate

References

<2. http://www.rcsb.org/structure/4ZJV 3. https://www.ncbi.nlm.nih.gov/pubmed/25735773 4. https://www.ncbi.nlm.nih.gov/pubmed/16377102 5. https://www.ebi.ac.uk/pdbe/entry/pdb/4zjv/citations>

Personal tools